Pharmacy Plus Limited

pharmacyplus.co.uk

Pharmacy Plus is a leading pharmacy group specialising in medicines management solutions for care homes in the UK. The company has a long heritage of innovation and influence within the Care Home sector, being the first UK Pharmacy organisation to focus solely on the specific needs of residents and professional colleagues working within this industry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

XERIS BIOPHARMA ENTERS INTO AGREEMENT FOR $30 MILLION PRIVATE PLACEMENT

Xeris Biopharma Holdings | January 04, 2022

news image

Xeris Biopharma Holdings, Inc. a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on January 2, 2022, it entered into a securities purchase agreement in connection with a private placement with an affiliate of Armistice Capital, LLC for aggregate gross proceeds of approximately $30.0 million. The Private Placement is expected to close on or around January 3, 2022.
Read More

INTRAVACC RECEIVES US NIH/NIAID CONTRACT TO DEVELOP ENTEROVIRUS D68 VACCINE

Intravacc | September 08, 2020

news image

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (...

Read More

PHARMA TECH

PERFORMANCE VALIDATION JOINS VALGENESIS PARTNER PROGRAM AS SERVICE PARTNER FOR THE U.S. MARKET

PR Newswire | January 24, 2024

news image

ValGenesis Inc., the market leader in enterprise validation lifecycle management systems (VLMS), and Performance Validation, Inc. a 100% employee-owned company serving the life sciences industry since 1988, have partnered to deliver unique compliance-focused digital validation solutions for life sciences companies in the US. Performance Validation is an industry leader with over 30 years of experience in analyzing, identifying, and testing the most critical elements of the manuf...

Read More

Research

ALGERNON PHARMACEUTICALS SIGNS AGREEMENT WITH CHARLES RIVER LABORATORIES FOR DMT PRECLINICAL STUDIES

Algernon Pharmaceuticals, Charles River Laboratories | February 11, 2021

news image

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that is has signed an agreement with Charles River Laboratories for preclinical studies of AP-188 ("N,N-Dimethyltryptamine or DMT") for the Company's stroke clinical research program. Algernon's preclinical study of DMT will be conducted at the Charles River research facility in Finland. Charles River Laboratories, Inc. is an American corporation specializing ...

Read More
news image

Business Insights

XERIS BIOPHARMA ENTERS INTO AGREEMENT FOR $30 MILLION PRIVATE PLACEMENT

Xeris Biopharma Holdings | January 04, 2022

Xeris Biopharma Holdings, Inc. a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on January 2, 2022, it entered into a securities purchase agreement in connection with a private placement with an affiliate of Armistice Capital, LLC for aggregate gross proceeds of approximately $30.0 million. The Private Placement is expected to close on or around January 3, 2022.
Read More

news image

INTRAVACC RECEIVES US NIH/NIAID CONTRACT TO DEVELOP ENTEROVIRUS D68 VACCINE

Intravacc | September 08, 2020

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (...

Read More
news image

PHARMA TECH

PERFORMANCE VALIDATION JOINS VALGENESIS PARTNER PROGRAM AS SERVICE PARTNER FOR THE U.S. MARKET

PR Newswire | January 24, 2024

ValGenesis Inc., the market leader in enterprise validation lifecycle management systems (VLMS), and Performance Validation, Inc. a 100% employee-owned company serving the life sciences industry since 1988, have partnered to deliver unique compliance-focused digital validation solutions for life sciences companies in the US. Performance Validation is an industry leader with over 30 years of experience in analyzing, identifying, and testing the most critical elements of the manuf...

Read More
news image

Research

ALGERNON PHARMACEUTICALS SIGNS AGREEMENT WITH CHARLES RIVER LABORATORIES FOR DMT PRECLINICAL STUDIES

Algernon Pharmaceuticals, Charles River Laboratories | February 11, 2021

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that is has signed an agreement with Charles River Laboratories for preclinical studies of AP-188 ("N,N-Dimethyltryptamine or DMT") for the Company's stroke clinical research program. Algernon's preclinical study of DMT will be conducted at the Charles River research facility in Finland. Charles River Laboratories, Inc. is an American corporation specializing ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us